Markus Bickel

Summary

Affiliation: Zentrum der Inneren Medizin
Country: Germany

Publications

  1. doi request reprint Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls
    Markus Bickel
    Department of Infectious Disease, JW Goethe University, Frankfurt, Germany
    HIV Clin Trials 14:175-81. 2013
  2. doi request reprint End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years
    M Bickel
    Department of Infectious Disease, Goethe University, Frankfurt Main, Germany
    HIV Med 14:127-35. 2013
  3. ncbi request reprint Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients
    Markus Bickel
    HIVCENTER, Frankfurt, Germany
    AIDS 24:F31-5. 2010
  4. doi request reprint Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients
    Markus Bickel
    HIVCENTER, Clinic of the Goethe University, Frankfurt, Germany
    Clin Infect Dis 52:122-7. 2011
  5. doi request reprint Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy
    Christoph Stephan
    Infectious Diseases Unit at Medical Department No 2, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    Med Microbiol Immunol 202:117-24. 2013
  6. doi request reprint Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment
    Pavel Khaykin
    HIVCENTER, Department of Internal Medicine II, and Institute of Medical Virology, Hospital of the Johann Wolfgang Goethe University, Frankfurt and HIV Laboratory, Therapia GmbH, c o Auguste Viktoria Hospital, Berlin, Germany
    Ther Drug Monit 36:192-201. 2014
  7. pmc Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir
    Markus Bickel
    HIVCENTER, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    J Antimicrob Chemother 65:999-1004. 2010
  8. doi request reprint Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting
    Annette Haberl
    HIVCENTER, Medical Clinics II, J W Goethe University Hospital, Frankfurt am Main, Germany
    Eur J Clin Pharmacol 66:375-81. 2010
  9. pmc Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes
    Martin Stürmer
    Johann Wolfgang Goethe University Hospital, Institute for Medical Virology, Frankfurt, Germany
    Antimicrob Agents Chemother 55:5362-6. 2011
  10. ncbi request reprint Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy
    Markus Bickel
    HIV Medical Treatment and Research Unit, Frankfurt, Germany
    Scand J Infect Dis 40:36-9. 2008

Detail Information

Publications14

  1. doi request reprint Immune response after a single dose of the 2010/11 trivalent, seasonal influenza vaccine in HIV-1-infected patients and healthy controls
    Markus Bickel
    Department of Infectious Disease, JW Goethe University, Frankfurt, Germany
    HIV Clin Trials 14:175-81. 2013
    ..Immune response rates following influenza vaccination are often lower in HIV-infected individuals. Low vitamin D levels were correlated with weak immune response in cancer patients and are known to be lower in HIV-infected patients...
  2. doi request reprint End-stage renal disease and dialysis in HIV-positive patients: observations from a long-term cohort study with a follow-up of 22 years
    M Bickel
    Department of Infectious Disease, Goethe University, Frankfurt Main, Germany
    HIV Med 14:127-35. 2013
    ..Renal disease is a common and serious complication in HIV-infected patients...
  3. ncbi request reprint Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV-1-infected patients
    Markus Bickel
    HIVCENTER, Frankfurt, Germany
    AIDS 24:F31-5. 2010
    ..To determine rates of seroconversion after single vaccination with a novel split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009) in HIV-1-infected patients (ClinicalTrials.gov Identifier: NCT01017172)...
  4. doi request reprint Immune response after two doses of the novel split virion, adjuvanted pandemic H1N1 influenza A vaccine in HIV-1-infected patients
    Markus Bickel
    HIVCENTER, Clinic of the Goethe University, Frankfurt, Germany
    Clin Infect Dis 52:122-7. 2011
    ..gov NCT01017172)...
  5. doi request reprint Impact of HIV-1 replication on immunological evolution during long-term dual-boosted protease inhibitor therapy
    Christoph Stephan
    Infectious Diseases Unit at Medical Department No 2, Hospital of the Johann Wolfgang Goethe University, Frankfurt, Germany
    Med Microbiol Immunol 202:117-24. 2013
    ..Viral detection >200 copies/ml was associated with decreasing CD4-cell slopes and emergence of major mutations, supporting this as benchmark for virological failure definition on PI therapy...
  6. doi request reprint Lopinavir/ritonavir pharmacokinetics, efficacy, and safety in HIV and hepatitis B or C coinfected adults without symptoms of hepatic impairment
    Pavel Khaykin
    HIVCENTER, Department of Internal Medicine II, and Institute of Medical Virology, Hospital of the Johann Wolfgang Goethe University, Frankfurt and HIV Laboratory, Therapia GmbH, c o Auguste Viktoria Hospital, Berlin, Germany
    Ther Drug Monit 36:192-201. 2014
    ..Our objective was to investigate whether hepatitis coinfection without clinical signs of hepatic impairment is a cofactor altering lopinavir pharmacokinetics and influencing therapy outcome...
  7. pmc Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir
    Markus Bickel
    HIVCENTER, Goethe University Hospital, Theodor Stern Kai 7, 60590 Frankfurt, Germany
    J Antimicrob Chemother 65:999-1004. 2010
    ..The introduction of raltegravir, which is not metabolized by the cytochrome system, may allow concomitant treatment without dose adaptation...
  8. doi request reprint Atazanavir plasma concentrations are impaired in HIV-1-infected adults simultaneously taking a methadone oral solution in a once-daily observed therapy setting
    Annette Haberl
    HIVCENTER, Medical Clinics II, J W Goethe University Hospital, Frankfurt am Main, Germany
    Eur J Clin Pharmacol 66:375-81. 2010
    ..We performed a matched-pairs analysis on 24 patients (12 men/women) taking atazanavir/ritonavir 300/100 mg daily plus reverse transcriptase inhibitors, with (n = 12) or without (n = 12) methadone co-administration...
  9. pmc Comparison of drug resistance scores for tipranavir in protease inhibitor-naive patients infected with HIV-1 B and non-B subtypes
    Martin Stürmer
    Johann Wolfgang Goethe University Hospital, Institute for Medical Virology, Frankfurt, Germany
    Antimicrob Agents Chemother 55:5362-6. 2011
    ..Current algorithms appear suboptimal for interpretation of resistance to tipranavir in non-B subtypes; increased scores might reflect algorithm bias rather than "natural resistance."..
  10. ncbi request reprint Long-term effect on body composition and metabolic parameters after treatment with recombinant human growth hormone (r-hGH) in HIV-1 infected patients with lipodystrophy
    Markus Bickel
    HIV Medical Treatment and Research Unit, Frankfurt, Germany
    Scand J Infect Dis 40:36-9. 2008
    ..006). These results suggest that the achieved reduction of VAT using r-hGH in lipodystrophic HIV+ patients is in part maintained after a median follow-up of 9 months...
  11. pmc Renal AA-amyloidosis in intravenous drug users--a role for HIV-infection?
    Oliver Jung
    Department of Infectious Disease, Goethe University, Frankfurt Main, Germany
    BMC Nephrol 13:151. 2012
    ..Chronic renal disease is a serious complication of long-term intravenous drug use (IVDU). Recent reports have postulated a changing pattern of underlying nephropathy over the last decades...
  12. ncbi request reprint Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis
    Markus Bickel
    HIV Treatment and Research Unit, JW Goethe University, Frankfurt, Germany
    Scand J Infect Dis 37:520-2. 2005
    ..Plasma levels of efavirenz were 10 times the upper limit and remained elevated (at twice the upper limit) 4 weeks after cessation of therapy. Efavirenz resistance (K103N) developed and was probably due to 'functional' monotherapy...
  13. doi request reprint Identification of a new epitope for HIV-neutralizing antibodies in the gp41 membrane proximal external region by an Env-tailored phage display library
    Mingkui Zhou
    Georg Speyer Haus, Institute for Biomedical Research, Frankfurt, Germany
    Eur J Immunol 43:499-509. 2013
    ..Thus, this new epitope represents a promising candidate for further analysis in view of HIV vaccine development...
  14. ncbi request reprint Severe rhabdomyolysis, acute renal failure and posterior encephalopathy after 'magic mushroom' abuse
    Markus Bickel
    Department of Internal Medicine ICU, J W Goethe University, Frankfurt, Germany
    Eur J Emerg Med 12:306-8. 2005
    ..Magic mushrooms are becoming increasingly fashionable among drug users, as they are believed to be more harmless than other hallucinogenic designer drugs. So far, little is known about their possible severe side effects...